Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis

Thrombosis Research

Volumn 116, Issue 6, 2005, Pages 519-524

  Björkman, Jan Arne E ^a   Abrahamsson, Tommy I ^a   Nerme, Viveca K ^a   Mattsson, Christer J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Carboxypeptidase U; Coronary artery thrombosis; rt PA; TAFIa; Thrombolysis

Indexed keywords

3 (2 GUANIDINOETHYLTHIO) 2 (MERCAPTOMETHYL)PROPIONIC ACID; ALTEPLASE; PEPTIDE HYDROLASE INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART PERFUSION; HEART RATE; HEMODYNAMIC PARAMETERS; HYPOTHESIS; LYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; VASCULAR PATENCY;

3-MERCAPTOPROPIONIC ACID; ANIMALS; CARBOXYPEPTIDASE U; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; LYSINE CARBOXYPEPTIDASE; MALE; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 24944445159     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.02.009     Document Type: Article

References (20)

1. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase or both on coronary-artery patency, ventricular function and survival after myocardial infarction N Engl J Med 329 1993 1615 1622
2. E. Réganon, F. Ferrando, V. Vila, P. Villa, V. Martínez-Sales, and L. Fayos Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone Haemostasis 28 1998 99 105
3. N.J. Mutch, L.A. Robbie, and N.A. Booth Human thrombi contain an abundance of active thrombin Thromb Haemost 86 2001 1028 1034
4. A. Redlitz, F.A. Nicolini, J.L. Malycky, E.J. Topol, and E.F. Plow Inducible carboxypeptidase activity: a role in clot lysis in vivo Circulation 93 1996 1328 1330
5. C. Mattsson, J.A. Bjorkman, T. Abrahamsson, V. Nerme, K. Schatteman, and J. Leurs Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran) Thromb Haemost 87 2002 557 562
6. D. Hendriks, W. Wang, S. Scharpé, M.P. Lommaert, and M. van Sande Purification and characterization of a new arginine carboxypeptidase in human serum Biochim Biophys Acta 1034 1990 86 92
7. D.L. Eaton, B.E. Malloy, S.P. Tsai, W. Henzel, and D. Drayna Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma J Biol Chem 266 1991 21833 21838
8. L. Bajzar, J. Morser, and M. Nesheim TAFI, or plasma pro-carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex J Biol Chem 271 1996 16603 16608
9. C. de Vries, H. Veerman, and H. Pannekoek Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin J Biol Chem 264 1989 12604 12610
10. 78]-plasminogen activation by native tissue-type plasminogen activator and variants that lack either the Finger or Kringle-2 domain J Biol Chem 272 1996 2183 2191
11. L. Bajzar, M.E. Nesheim, and P.B. Tracy The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent Blood 88 1996 2093 2100
12. W. Wang, M.B. Boffa, L. Bajzar, J.B. Walker, and M.E. Nesheim A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor J Biol Chem 273 1998 27176 27181
13. P. Klement, P. Liao, and L. Bajzar A novel approach to arterial thrombolysis Blood 94 1999 2735 2743
14. C. Mattsson, J.-A. Björkman, and J.-C. Ulvinge Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis Fibrinolysis Proteolysis 11 1997 121 128
15. W. Wang, D. Hendriks, and S. Scharpé Carboxypeptidase U, a plasma carboxypepitidase with high affinity for plasminogen J Biol Chem 269 1994 15937 15944
16. R. Skidgel Basic carboxypeptidases: regulators of peptide hormone activity TIPS 9 1988 299 304
17. M. Quagraine A novel role for human plasma carboxypeptidase N: inhibition of plasminogen activation Health Sci, Pharmacol 63 12 2003 5779
18. V. Nerme, B. Åkerblom, A. Legnehed, L. Ericson, S. Scharpé, and D. Hendriks Carboxypeptidase U inhibitors increase the rate of fibrinolysis in a rat DIC model Fibrinolysis Proteolysis 14 Suppl. 1 2000 69
19. E. Blair, E. Nygren, and R.A. Cowley A spiral wire technique for producing gradually occlusive coronary thrombosis J Thorac Cardiovasc 48 1964 476 485
20. S. Roux, T. Tschopp, and H.R. Baumgartner Effects of napsagatran, a new synthetic thrombin inhibitor and heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model J Pharmacol Exp Ther 277 1996 71 78